Staphylococcus aureus Dormancy : Waiting for Insurgency
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Relapse infection usually results from resistance to the antibiotic, acquired genes, or persister cells. Persister cells are formed through mutation, reduced activity or metabolically inactive pathways induced by antibiotics, harassing conditions, low ATP, and malnutrition. These factors provide the ground for bacteria to grow slowly. Such a slow growth rate makes traditional antibiotics ineffective against persister cells. Staphylococcus aureus (S. aureus), in addition to this form, can be observed in Small Colony Variants (SCVs), L-forms, and dormant, all of which are characterized by at least one feature, i.e., slow growth. Despite their slow growth, they are metabolically active in terms of stringent SOS and cell wall stress responses. The stress response involves resistance against harassing conditions, and it survives until it is reactivated later. The present study aims to discuss the mechanisms of all persister cell formations, circumstances involved, gene mutation, and adoptable strategies against it.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current pharmaceutical biotechnology - 24(2023), 15 vom: 01., Seite 1898-1915 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nasser, Ahmad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 11.07.2023 Date Revised 18.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389201024666230411110002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355602202 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355602202 | ||
| 003 | DE-627 | ||
| 005 | 20231226064706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389201024666230411110002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355602202 | ||
| 035 | |a (NLM)37055886 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nasser, Ahmad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Staphylococcus aureus Dormancy |b Waiting for Insurgency |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Relapse infection usually results from resistance to the antibiotic, acquired genes, or persister cells. Persister cells are formed through mutation, reduced activity or metabolically inactive pathways induced by antibiotics, harassing conditions, low ATP, and malnutrition. These factors provide the ground for bacteria to grow slowly. Such a slow growth rate makes traditional antibiotics ineffective against persister cells. Staphylococcus aureus (S. aureus), in addition to this form, can be observed in Small Colony Variants (SCVs), L-forms, and dormant, all of which are characterized by at least one feature, i.e., slow growth. Despite their slow growth, they are metabolically active in terms of stringent SOS and cell wall stress responses. The stress response involves resistance against harassing conditions, and it survives until it is reactivated later. The present study aims to discuss the mechanisms of all persister cell formations, circumstances involved, gene mutation, and adoptable strategies against it | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a L forms | |
| 650 | 4 | |a Persister cell | |
| 650 | 4 | |a biofilm | |
| 650 | 4 | |a dormancy | |
| 650 | 4 | |a ribosome hibernation | |
| 650 | 4 | |a stringent response | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Jahanbakhshi, Shiva |e verfasserin |4 aut | |
| 700 | 1 | |a Soltan Dallal, Mohammad Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Banar, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Sattari-Maraji, Azin |e verfasserin |4 aut | |
| 700 | 1 | |a Azimi, Taher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d 2000 |g 24(2023), 15 vom: 01., Seite 1898-1915 |w (DE-627)NLM11369072X |x 1873-4316 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:15 |g day:01 |g pages:1898-1915 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389201024666230411110002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 15 |b 01 |h 1898-1915 | ||